Page 24 - 2021_03-Haematologica-web

A. Burchert
2011;103(11):893-905.
48. Ravandi F, Arana Yi C, Cortes JE, et al. Final
report of phase II study of sorafenib, cytara- bine and idarubicin for initial therapy in younger patients with acute myeloid leukemia. Leukemia. 2014;28(7):1543-1545.
49.Schlenk RF, Weber D, Fiedler W, et al. Midostaurin added to chemotherapy and continued single-agent maintenance therapy in acute myeloid leukemia with FLT3-ITD. Blood. 2019;133(8):840-851.
50. Wang ES, Tallman MS, Stone RM, et al. Low relapse rate in younger patients ≤60 years old with newly diagnosed FLT3-mutated acute myeloid leukemia (AML) treated with crenolanib and cytarabine/anthracycline. Blood. 2016;128(22):1071.
51. Ravandi F, Alattar ML, Grunwald MR, et al. Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation. Blood. 2013;121(23):4655-4662.
52. Strati P, Kantarjian H, Ravandi F, et al. Phase I/II trial of the combination of midostaurin (PKC412) and 5-azacytidine for patients with acute myeloid leukemia and myelodysplastic syndrome. Am J Hematol. 2015;90(4):276- 281.
53. Swaminathan M, Kantarjian HM, Daver N, et al. The combination of quizartinib with azacitidine or low dose cytarabine is highly active in patients (Pts) with FLT3-ITD mutated myeloid leukemias: interim report of a phase I/II trial. Blood. 2017;130(Suppl 1):723.
54. Esteve J, Schots R, Del Castillo TB, et al. PS1065 open-label study of gilteritinib, gilteritinib plus azacitidine, or azacitidine alone in newly diagnosed FLT3-mutated AML patients ineligible for intensive chemotherapy: results from the safety cohort. HemaSphere. 2019;3(S1):482.
55. Larson RA, Mandrekar SJ, Sanford BL, et al. An analysis of maintenance therapy and post-midostaurin outcomes in the interna- tional prospective randomized, placebo- controlled, double-blind trial (CALGB 10603/RATIFY [Alliance]) for newly diag- nosed acute myeloid leukemia patients with FLT3 mutations. Blood. 2017:130(Suppl 1):145.
56. Lee CJ, Savani BN, Mohty M, et al. Post- remission strategies for the prevention of relapse following allogeneic hematopoietic cell transplantation for high-risk acute myeloid leukemia: expert review from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Bone Marrow Transplant. 2019;54(4):519-530.
57. Bornhäuser M, Illmer T, Schaich M, et al. Improved outcome after stem-cell transplan- tation in FLT3/ITD-positive AML. Blood. 2007;109(5):2264-2265; author reply 2265.
58.Pidala J, Martens M, Anasetti C, et al. Factors associated with successful discontin- uation of immune suppression after allo- geneic hematopoietic cell transplantation. JAMA Oncol. 2019;6(1):e192974. Kharfan-Dabaja MA, Labopin M, Polge E, et al. Association of second allogeneic hematopoietic cell transplant vs donor lym- phocyte infusion with overall survival in patients with acute myeloid leukemia relapse. JAMA Oncol. 2018;4(9):1245-1253. Mathew NR, Baumgartner F, Braun L, et al. Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells. Nat Med. 2018;24(3):282-291. Yokoyama H, Lundqvist A, Su S, Childs R. Toxic effects of sorafenib when given early after allogeneic hematopoietic stem cell transplantation. Blood. 2010;116(15):2858- 2859.
phase 3 trial. Lancet Oncol. 2020;21(9):1201-
1212.
65. Walter RB, Gyurkocza B, Storer BE, et al.
Comparison of minimal residual disease as outcome predictor for AML patients in first complete remission undergoing myeloabla- tive or nonmyeloablative allogeneic hematopoietic cell transplantation. Leukemia. 2015;29(1):137-144.
66. Araki D, Wood BL, Othus M, et al. Allogeneic hematopoietic cell transplanta- tion for acute myeloid leukemia: time to move toward a minimal residual disease- based definition of complete remission? J Clin Oncol. 2016;34(4):329-336.
67.Levis M, Shi W, Chang K, et al. FLT3 inhibitors added to induction therapy induce deeper remissions. Blood. 2020;135 (1):75-78.
68. DiNardo CD, Jonas BA, Pullarkat V, et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med. 2020;383(7):617-629.
69. Stein EM, DiNardo CD, Fathi AT, et al. Molecular remission and response patterns in patients with mutant-IDH2 acute myeloid leukemia treated with enasidenib. Blood. 2019;133(7):676-687.
70. DiNardo CD, Stein EM, de Botton S, et al. Durable remissions with ivosidenib in IDH1-mutated relapsed or refractory AML. N Engl J Med. 2018;378(25):2386-2398.
71. Wei AH, Döhner H, Pocock C, et al. The QUAZAR AML-001 maintenance trial: results of a phase III international, random- ized, double-blind, placebo-controlled study of CC-486 (oral formulation of azacitidine) in patients with acute myeloid leukemia (AML) in first remission. Blood. 2019;134 (Suppl 2):LBA-3.
72. Huls G, Chitu DA, Havelange V, et al. Azacitidine maintenance after intensive chemotherapy improves DFS in older AML patients. Blood. 2019;133(13):1457- 1464.
73. Gao L, Zhang Y, Wang S, et al. Effect of rhG- CSF combined with decitabine prophylaxis on relapse of patients with high-risk MRD- negative AML after HSCT: an open-label, multicenter, randomized controlled trial. J Clin Oncol. 2020;38(36):1903277.
59.
60.
61.
62.
63.
64.
Maziarz RT, Levis M, Patnaik MM, et al. Midostaurin after allogeneic stem cell trans- plant in patients with FLT3-internal tandem duplication-positive acute myeloid leukemia. Bone Marrow Transplant. 2020 Dec 7 [Epub ahead of print]
Burchert A, Bug G, Fritz LV, et al. Sorafenib maintenance after allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia with FLT3-internal tandem dupli- cation mutation (SORMAIN). J Clin Oncol. 2020;38(26):2993-3002.
Xuan L, Wang Y, Huang F, et al. Sorafenib maintenance in patients with FLT3-ITD acute myeloid leukaemia undergoing allo- geneic haematopoietic stem-cell transplanta- tion: an open-label, multicentre, randomised
670
haematologica | 2021; 106(3)